Health
Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test – News-Medical.net
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce…
Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.
Avacta is developing several coronavirus tests using Affimer binders that are highly…
-
General12 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News18 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business20 hours agoBell Potter names the best ASX shares to buy in October
-
Noosa News24 hours agoResilience features in Sunshine Coast Open House